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ABSTRACT 
TESTING THE EFFICACY OF TRANSCRANIAL  
MAGNETIC STIMULATION (TMS) IN TREATING 
DEPRESSION IN PATIENTS WITH COGNITIVE IMPAIRMENT 
Daniel Robert Schaffer 
Old Dominion University, 2018 
Director: Dr. Barbara Winstead 
 
The purpose of this study is to (1) examine the efficacy of Transcranial Magnetic 
Stimulation (TMS) in treating depression among individuals with cognitive impairment and (2) 
to examine if TMS is capable of facilitating cognitive improvements independent of mood 
improvements. Mild cognitive impairment (MCI) is often seen as a pre-clinical stage to 
dementia, and depressive disorders are highly prevalent among both MCI and dementia. There is 
a large body of research that has linked depressive disorders as a prodromal symptom of MCI 
and the later development of dementia. While some researchers debate whether or not this link 
between depression and MCI/dementia is a true prodromal relationship, or if depression is 
independently comorbid with MCI/dementia, it remains clear that these disorders occur together 
in high prevalence rates.  
The goal of this study was to determine whether or not Transcranial Magnetic 
Stimulation (TMS) might demonstrate treatment efficacy in treating depressive symptoms among 
individuals who meet MCI criteria. TMS has been previously approved by the FDA to treat 
major depressive disorder (MDD); however, very few research studies have been performed to 
analyze TMS’ ability in treating MDD among individuals with MCI.  
By analyzing treatment data from individuals who do and do not meet MCI criteria, TMS 
does appear to demonstrate positive treatment efficacy for treating depressive symptoms among 
 
 
individuals who meet MCI criteria. TMS also appears to be equally efficacious in treating 
depressive symptoms among this group in comparison to individuals without MCI. TMS also 
produces positive changes in neurocognitive functioning, both in the MCI and non-MCI groups; 
however, the results show that these changes in neurocognitive functioning likely occur as a 
function of depressive symptom reduction. 
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INTRODUCTION 
Literature Review 
Depression is a common phenomenon among individuals with mild cognitive impairment 
(MCI) and dementia. According to many researchers, MCI is often a precursor to dementia, and 
MCI is often referred to as pre-dementia, pre-clinical phase, or transitional stage to developing a 
dementia diagnosis (Albert, et al., 2010; Alzheimer’s Association, 2016; Gualtieri & Johnson, 
2005; Kelley & Peterson, 2007; Nardone, et al., 2014; National Institute on Aging, 2015; 
Peterson, 2007; Peterson, 2013). Specific conversion rates from MCI to dementia diagnoses 
seem to vary among the research. The average conversion rate is approximately 10-15% 
(Mitchell & Shiri-Feshki, 2009); however, the conversion rate has been measured up to 40% 
(Farias, Mungas, Reed, Harvey, & DeCarli, 2009; Mitchell & Shiri-Freskhi, 2009).  
Current methods for treating depression in individuals with MCI and dementia, namely 
antidepressant medications (e.g., SSRIs) and electroconvulsive therapy (ECT), have been 
scrutinized within the body of research due to concerns about their efficacy and safety among 
this population. The purpose of this research study is to examine the effects of transcranial 
magnetic stimulation (TMS) on treating depression and improving cognitive functioning among 
individuals with MCI.  
There is markedly little research on MCI, as it is often difficult to detect in its beginning 
stages, and it often goes undiagnosed until it develops into dementia (Saykin & Rabain, 2014). 
According to the Alzheimer’s Association (2016), approximately 60-80% of all dementia 
diagnoses are Alzheimer’s disease (AD; p. 6). Because of the disproportionate amount of AD in 
comparison to the many other forms of dementia, a large bulk of the research body focuses on 
AD, leaving other forms of dementia underrepresented in the literature.  
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Dementia, also known as Major Neurocognitive Disorder (MND), is a growing 
phenomenon around the world. According to the World Health Organization (2015), the number 
of people living with dementia diagnoses in 2015 was approximately 47.47 million people. This 
number was projected to increase to 76.36 million people worldwide in 2030 (60.86% increase) 
and up to 135.46 million people worldwide in 2050 (77.40% increase from 2030; 185.36% 
increase from 2015). This increase in prevalence rates is likely due to the growing population 
and increasing life expectancy of the general population (Alexopolous & Kelly, 2009; 
Alzheimer’s Association, 2016; Kelly & Peterson, 2007; National Institute on Aging, 2015; 
Rabey & Dobrenevsky, 2016; Saykin & Rabin, 2014). While the precise numerical increase 
tends to vary across sources, it is clear that the increase in MCI/dementia is a serious issue 
around the world. 
 Common comorbid psychological diagnoses with dementia are depressive disorders. The 
Alzheimer’s Association (2016) has identified depression as a possible early symptom in 
developing MCI/dementia. While there is some debate in the literature as to whether depression 
is a result of neurophysiological changes in the brain caused by dementia, or if depression could 
be an early symptom or risk factor of developing MCI/dementia, research is providing increasing 
support for depression as prodromal to MCI and dementia.  
 Depression in the elderly population may first appear as symptoms of cognitive decline, 
especially in the following areas of cognition: information processing speed, episodic memory, 
and executive function (Story, Potter, Attix, Welsh-Bohmer, & Steffens, 2008). Story, et al. 
(2008) found that individuals with Major Depressive Disorder displayed performance levels on 
neurocognitive measures similar to those who demonstrate true cognitive decline. However, after 
treating for depression, cognitive scores increased in a progression towards average functioning 
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(Story, et al., 2008), thus highlighting the possibility that depressive disorders are linked with 
outward declines in cognitive functioning.  
 According to an extensive narrative review by Byers and Yaffe (2011), “depression can 
impair cognitive functioning leading to ‘pseudodementia’” (p. 2). By calling the outward 
cognitive deficits brought about by depression “pseudodementia,” the line between the two 
disorders (i.e. dementia and depression) is blurred. When these two disorders occur together, it 
can become difficult for clinicians to determine their exact relationship (Byers & Yaffe, 2011). 
This information is also supported by Peterson (2007), and Saykin and Rabin (2014), who stated, 
“…depression alone can cause significant cognitive impairment” (p. 249). The term 
“pseudodementia,” or “depressive pseudodementia,” has appeared across the body of research as 
a means to describe this relationship between depressive disorders and cognitive symptomology 
(Bieniek, et al., 2014; Byers & Yaffe, 2011; Hancock & Larner, 2014; Heser, et al., 2016; Paula, 
et al., 2013). 
There is increasing evidence supporting depression as a prodrome to dementia. In other 
words, depression occurring later in life could potentially be viewed as a harbinger of developing 
MCI and subsequent dementia (Hesser, et al., 2016; Saykin & Rabin, 2014; Segal, Coolidge, 
Cahill, & O’Riley, 2008).  A research study that sought to examine this potential prodromal link 
between depression and dementia was that of Han, et al. (2008). The findings of this study 
showed that at 12-month follow up appointments, over half of the initial patients (n = 281, age 
65 and older) who were diagnosed with major or minor depression, as defined by the DSM-IV, 
scored significantly lower on the Mini-Mental State Examination (MMSE) than upon intake. 
This decline in cognitive status remained significant after successfully treating the depressive 
disorder (Han, et al., 2008), indicating that the cognitive deficits present among the participants 
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was not caused by a “depressive pseudodementia.” As a result, this study does provide support 
that depression may be viewed a potential prodromal factor to cognitive decline.  
Thomas and Bennett (2014) examined correlations between early-life depression and 
later-life onset of dementia. Their narrative review provided evidence for two hypotheses: (1) 
early-life depression can act as a potential risk factor for later-life dementia, and (2) later-life 
depression can be viewed as a prodrome to the onset of dementia. According to their review, 
both depression and dementia were associated with white matter alterations in the brain, 
indicating either (1) shared risk factors, or (2) shared pattern of neurological damage (Thomas & 
Bennett, 2014). Once again, the research provides increasing support for the notion that 
depression and dementia are linked in a prodromal relationship, meaning depression is a possible 
risk factor or indicator for the onset of MCI/dementia and related cognitive declines. 
Mirza, et al. (2016) conducted a longitudinal study embedded within a much larger study 
(the Rotterdam Study), ongoing since 1990, during which participating individuals were 
monitored for any major events. Among the cohort selected for this longitudinal study (n = 
3,325), the researchers found a significant relationship between high depressive symptoms later 
in life and the later onset of cognitive decline, MCI, and AD after the following potential 
confounds were controlled: age, sex, presence of the APOEε4 allele, education level, body-mass 
index (BMI), smoking habits, alcohol consumption, general cognition (MMSE score), use of 
antidepressants, prevalent hypertension, Type 2 Diabetes or the use of any anti-diabetic 
medications, and previous myocardial infarction and stroke activity (Mirza, et al., 2016). These 
results provide further evidence for depression acting as a prodromal factor for cognitive decline, 
MCI, and dementia.  
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Castilla-Puentes and Habeych (2010) researched specific links between certain types of 
depressive disorders and dementia diagnoses. They analyzed the prevalence of different subtypes 
of depressive disorders in patients with AD (n = 2,947), vascular dementia (VaD; n = 725), and 
unspecified dementia (UD; n = 2,768). The subtypes of depressive disorders that were studied, 
based on the ICD-9 diagnostic codes, were major depressive disorder, depressive disorder not 
otherwise specified, dysthymic disorder, depressive psychosis, and adjustment disorder with 
depressive symptoms. They found that the overall prevalence rate of depressive disorders among 
individuals with dementia (n = 6,440) was 27.41%. Specifically, the prevalence rates were 
44.14% in VaD; 32.48% in UD; and 18.53% in AD. VaD was found to have the highest rate of 
comorbid diagnoses of depressive disorders, including depressive disorder not otherwise 
specified, major depressive disorder, and dysthymic disorder. Adjustment disorder with 
depressive symptoms was most common among the UD group, and depressive psychosis was 
similar among all dementia groups (Castilla-Puentes & Habeych, 2010). Once again, it is evident 
that depressive disorders and dementia are highly linked in some way. Based on this evidence, it 
appears that VaD has the highest prevalence rates of depressive comorbidity among the other 
forms of dementia, with AD and UD showing significant comorbidity as well.  
Byers and Yaffe (2011) provided further explanations for this apparent link between 
depression and dementia with their extensive narrative review. They discovered that 
approximately 20% of patients with AD, and 50% of patients with VaD, had a comorbid 
diagnosis of major depressive disorder (MDD). In order to explain this link, they developed four 
equally-plausible hypotheses based on their review of the literature: “(1) depressive symptoms 
often occur among patients with dementia; (2) depression may be a psychological reaction to 
early cognitive deficits; (3) depression can impair cognitive functioning leading to a 
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‘pseudodementia’ presentation; and (4) depression may be a risk factor or early symptom of 
dementia” (Byers & Yaffe, 2011, p. 2), particularly for VaD. However, Byers and Yaffe (2011) 
also state that the exact relationship between late-life depression and MCI/dementia is “unclear” 
(p. 8). 
While the current body of literature is mixed, and no empirical consensus has been 
reached as to the exact nature of late-life depression and MCI/dementia, there does appear to be 
enough empirical support for the claim that late-life depression is prodromal to the development 
of MCI/dementia. As such, early intervention and treatment for late-life depression may act in a 
protective manner against the further development of MCI/dementia. While depressive 
symptoms may present in a depressive pseudodementia manifestation, empirical evidence has 
suggested that, if depressive symptoms are left untreated, further cognitive decline is highly 
likely, thus resulting in a more severe MCI/dementia diagnosis. However, if accurate diagnoses 
are made early and interventions are implemented, the continual neurodegeneration of 
“depressive pseudodementia” into true MCI/dementia may be prevented. 
The most widely used method of treating depression among individuals with dementia 
diagnoses is the use of antidepressant medications, specifically selective serotonin reuptake 
inhibitors (SSRIs). There is some research that claimed SSRIs become less effective in older 
populations, such as the geriatric dementia population (Kitching, 2015, p. 209; McDonald, 2016, 
p. 1130). Supporting this claim, Farina, Morrell, and Banarjee (2016) conducted a literature 
review to examine the efficacy of antidepressant medications, specifically SSRIs, in the 
depressed dementia population. After reviewing 36 randomized controlled studies (n = 3,386), 
they found that the most significant effect of SSRIs was for mitigating agitation in the depressed 
dementia population, a claim which is also supported by the National Institute of Aging (2015, p. 
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37); however, their findings reflected a lack of efficacy for SSRIs in treating depressive disorders 
among individuals with dementia (Farina, et al., 2016). It is important to note that the research 
included in the narrative review was predominantly concerned with AD, with few included 
studies analyzing the effects of SSRIs among individuals with VaD, fronto-temporal dementia 
(FTD), or dementia not specified. Specific analyses of the effects of SSRIs among these subtypes 
of dementia are not provided (Farina, et al., 2016).  
Enache, Winblad, and Aarsland (2011) provided further support for the lack of treatment 
efficacy of antidepressants for depression among dementia populations. In their narrative review, 
they found eleven studies (n = 1,514) that examined the effects of antidepressant medications on 
treating depression among individuals with dementia. Results were largely inconsistent with each 
other. Byers and Yaffe (2011) also stated that the research body at the time demonstrated a lack 
of treatment differences between placebo and treatment groups. Due to these inconsistencies, the 
efficacy of antidepressants for individuals with MCI/dementia was called into question (Byers & 
Yaffe, 2011; Enache, et al., 2011).  
Other treatment methods for depression in individuals with dementia include some 
cognitive psychosocial strategies such as reminiscence therapy, music, cognitive stimulation, 
conversation, and physical activity when it can be applied (Enache, et al., 2011; Moyle, Hsu, 
Lieff, & Vernooij-Dassen, 2010). However, there is little research to support the efficacy of these 
cognitive and psychosocial strategies. Due to cognitive impairment, many forms of cognition-
based therapies, including Cognitive Behavioral Therapy (CBT), are likely to be less effective 
for patients with cognitive impairment and dementia (Enache, et al., 2011).  
In a narrative review by Kolshus, Jelovac, and McLaughlin (2016), two types of brief-
pulse ECT were found to be the most commonly used when treating depression among 
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individuals with dementia: bitemporal electrode placement and right unilateral ECT. Of these 
two methodologies, bitemporal electrode placement was found to be the most commonly used. 
Seven ECT studies (n = 792) were included in the review, analyzing both forms of ECT 
treatment methods. Both bilateral electrode placement and unilateral ECT have been shown to 
decrease depressive symptomatology in degrees that are both clinically and statistically 
significant; however, high-dose unilateral ECT treatments have shown fewer cognitive side-
effects than moderate-dose bitemporal treatments (Kolshus, et al., 2016).  
ECT as a general form of treatment does cause certain cognitive side effects after 
treatment, some remaining for a short duration after the treatment, and others lasting slightly 
longer. Immediate disorientation is the most frequent side-effect, and it usually dissipates within 
the first hour after treatment (Kolshus, et al., 2016). Many other cognitive side effects tend to last 
for approximately two to three weeks after treatment. Bilateral ECT has been shown to create 
“more global cognition deficits, delayed verbal memory, and autobiographical memory 
impairments in comparison to unilateral ECT” (Kolshus, et al., 2016, p. 519). Unilateral ECT 
treatment has also been associated with “decreases in verbal learning, delayed verbal memory, 
visual recognition impairments, and semantic memory retrieval deficits” (Kolshus, et al., 2016, 
p. 519). While research has shown that bilateral ECT methodologies produce more cognitive 
side-effects than unilateral ECT methodologies, the fact remains that both methodologies create 
cognitive side-effects that can last for weeks, or longer, after treatment sessions. Moreover, 
elderly patients with cognitive deficits without dementia diagnoses, such as those with MCI or 
cognitive deficits as a result of depressive disorders (Byers & Yaffe, 2011; Saykin & Rabin, 
2014; Story, et al., 2008), are more susceptible to these cognitive side-effects (Dybedal, Tanum, 
Sundet, & Bjølseth, 2015).  
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Vagal Nerve Stimulation (VNS) is another FDA approved treatment for long-term, 
treatment-resistant depression for individuals age 18 and older. According to McDonald (2016), 
“there are no published studies currently addressing VNS [specifically] in the elderly” (p. 1133); 
however, analysis of patients age 65 and older receiving VNS in a larger registry sample showed 
promising results for its efficacy in improving depressive symptoms among the aforementioned 
individuals. It is important to note, though, that individuals age 65 and older comprised only 20 
of the total 500 patients in the overall registry study (McDonald, 2016), thus providing too little 
information to come to concrete conclusions about VNS in the geriatric population. VNS also 
requires invasive surgery, during which surgeons must attach an electrode onto the left vagus 
nerve. This electrode is also connected to a stimulator implanted in the individual’s chest wall. 
The devise releases electrical impulses that are sent via the stimulator in order to create 
therapeutic effects (McDonald, 2016, p. 1133). Because this is such an invasive procedure, it 
may not be a proper choice for elderly individuals with MCI or dementia diagnoses.  
Based on the current treatment information found within the body of literature, it is clear 
that individuals with MCI/dementia and comorbid depressive disorders are in need of an 
alternative form of treatment. The goal of this research project was to determine if Transcranial 
Magnetic Stimulation (TMS) may be an efficacious form of treatment for this population. TMS 
has already been deemed an efficacious treatment method for individuals with depression 
(Lannone, Cruz, Brazil-Neto, & Boechat-Barros, 2016; Magnezi, Aminov, Shmuel, Dreifuss, & 
Dannon, 2016; McDonald, 2016; Perera, et al., 2016; Wani, Trevino, Marnell, & Husain, 2013), 
and it has been approved by the FDA as a treatment method for treatment-resistant depression 
(U.S. DHHS, FDA, & CDRH, 2011). TMS has also been found to be more cost effective and 
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patient-preferred over ECT (Magnezi, et al., 2016) and other conventional forms of treatment 
(Simpson, Welch, Kozel, Demitrack, & Nahas, 2009).  
Brain stimulation as a therapeutic clinical technique began in the early 20th century, 
particularly with the development of ECT in 1937 (Horvath, Perez, Farrow, Fregni, & Pascual-
Leone, 2011). Faraday’s discovery (as cited in Horvath, et al., 2011) of electromagnetic 
induction ultimately marked the beginning of magnetic pulse stimulation as a therapeutic 
approach. The use of magnetic pulse stimulation was not developed until 1910, and it did not see 
human nervous system application until 1965 (Horvath, et al., 2011). After the first official TMS 
device was created in 1985, the applications of magnetic stimulation have expanded to what they 
are today, including the FDA approved treatment of depressive disorders (Horvath, et al., 2011; 
U.S. DHHS., et al., 2011).  
TMS is a neuro-stimulation technique in which parts of the neocortex, approximately 2-3 
cm deep, and underlying areas of the brain through transynaptic neuro-pathways can be 
innervated by brief, noninvasive magnetic currents. The electrical currents in the brain are 
enervated by brief magnetic fields discharged by a coil placed against the scalp, targeting a 
specific area of the brain (Cowey, 2005). Unlike other forms of neuro-stimulation, such as ECT, 
TMS does not directly produce electrical currents to stimulate the brain. Instead, TMS promotes 
neural activity via magnetic fields. ECT also typically requires anesthesia to facilitate muscle 
relaxation during the procedure (American Psychiatric Association, 1978), whereas TMS can be 
applied to patients while awake and alert without anesthesia. Due to the non-invasive nature of 
TMS, and its ability to increase neuroplasticity (Pascual-Leone, et al., 1999) and innervate areas 
of the brain associated with depressive symptoms (Arns, Drinkenburg, Fitzgerald, & Kenemans, 
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2012), TMS has been approved by the FDA as a treatment for treatment-resistant depression 
(U.S. DHHS, et al., 2011).  
The success rates of TMS in its ability to treat treatment-resistant depression vary 
throughout the literature, mainly due to many studies using relatively small sample sizes. 
However, some meta-analyses have found TMS to be up to 80% effective in treating treatment-
resistant depression (treatment success defined as the absence of depressive symptom relapse; 
Janicak & Dokucu, 2015), indicating that it is likely able to reduce depressive symptoms with 
little risk of relapse among 80% of the treatment-resistant population. Research has also shown 
TMS to produce long-lasting treatment effects after cessation of treatment (Machado, et al., 
2013; Simpson, et al., 2009). In fact, some research indicates that TMS may have long-lasting 
benefits for up to 84.2% of patients who see clinical improvement of their depressive symptoms, 
with effects maintained at 6-month follow-up (treatment benefits defined by the absence of 
depressive symptom relapse; Janicak, et al., 2010). However, these success rates are found 
within younger to average age adult samples. Not enough data pertaining specifically to geriatric 
samples are available for success rates to be formulated for this group.  
TMS as a treatment method for elderly and geriatric populations has been questioned by 
research, primarily due to “lack of evidence [for this age group],” lack of age-cohort inclusion, 
and “a lack of safety information” (Sabesan, et al., 2015, p. 170-171); however, Sabesan, et al. 
(2015) found evidence to support the use of TMS in the elderly/geriatric population. In their 
narrative review, they cited several studies in which there was no participant attrition due to 
adverse side-effects or safety complications. One study cited by Sabesan, et al. (2015), 
conducted by Jorge, Moser, Acion, and Robinson (2008), included two separate experiments 
(total n = 92, mean age = 63.85, age range unavailable). Both experiments addressed the safety 
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and efficacy of TMS in the elderly/geriatric population. According to Jorge, et al. (2008), the 
active treatment and sham treatment groups did not differ significantly in frequency of adverse 
side effects, and the active treatment group also showed significant improvements in 
symptomology, thus providing support for the safety and efficacy of TMS for this population.  
There has been some concern within the literature as to whether or not TMS could be a 
viable treatment method for depression among individuals with MCI/dementia diagnoses. 
Cortical atrophy is often prevalent among individuals with MCI, and it is a key characteristic 
among many forms of dementia. As a result, it may be more difficult for TMS methodologies to 
effectively stimulate the targeted areas. In vascular dementia particularly, certain 
neuroanatomical circuits are disrupted, potentially making TMS less effective in neural 
activation (McDonald, 2016). However, there is evidence within the body of research that 
supports the claim that TMS can be used to increase cortical and neural excitability and neural 
plasticity among individuals with dementia diagnoses (Alberici, et al., 2008; Elder & Taylor, 
2014; Issac, Chandra, & Nagaruju, 2013; Luber & Lisanby, 2014; Nardone, et al., 2015; Pennisi, 
et al., 2006), thus providing a counter-argument to many criticisms of the efficacy of TMS for 
this population. 
Because TMS can stimulate and increase cortical and neural excitability and neural 
plasticity, it may be possible for TMS to improve cognitive performance among individuals with 
MCI and varying levels of dementia. While a vast majority of the research in this particular area 
has focused solely on AD, many studies have cited direct cognitive improvements among 
individuals ages 55-85 as a result of TMS treatment programs (Bentwich, et al., 2011; Cotelli, et 
al., 2006; Lee, Choi, Oh, Sohn, & Lee, 2016; Nardone, et al., 2014; Rabey & Dobrenevsky, 
2016). However, it should also be noted that many of these studies also incorporated a form of 
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cognitive training to be performed either during or alongside the TMS treatment regimen 
(deemed TMS-Cog; Bentwich, et al., 2011; Lee, et al., 2016; Rabey & Dobrenevsky, 2016). 
Because of the combination of these two methodologies, it is unclear whether or not TMS alone 
may have a significant influence on cognitive performance.   
One particular study conducted by Chappell (2016) found that TMS provides an 
efficacious treatment method for improving cognitive functioning. The sample from this study (n 
= 20) had a mean age of 42.35 (SD = 12.50), was predominantly female (75%), and was 
predominantly Caucasian (90%). Specifically, Chappell (2016) examined three cognitive 
domains in individuals with DSM-IV diagnoses of Major Depressive Disorder: executive 
functioning, complex attention, and cognitive flexibility. All three of these cognitive areas 
significantly improved after the first two weeks of treatment and stabilized after the second 
week. No significant improvements in cognition were noted after the second week of treatment 
(Chappell, 2016).  
Statement of Purpose 
For the purpose of this research study, there are two primary research questions of 
interest: (1) can Transcranial Magnetic Stimulation (TMS) be used effectively to treat depression 
in patients diagnosed with mild cognitive impairment (MCI), and (2) can TMS be used to 
improve cognitive functioning among the aforementioned individuals independent of mood 
improvements? We hypothesize that TMS treatment will improve depression levels as well as 
cognitive impairment, and the improvement in cognitive impairment will be independent of 
changes in depression levels. We also hypothesize that any treatment differences among 
depressive symptoms between individuals with MCI and individuals without MCI will not be 
statistically different – TMS will be equally efficacious in treating depressive symptoms for both 
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groups. The efficacy in treating depressive symptoms among non-cognitively impaired 
individuals has been well established in the literature; it is a goal of this study to determine if 
these treatment outcomes (i.e. clinically/statistically improved depressive symptoms) also extend 
to individuals with MCI.  
Methodology 
Sample 
 Data were derived from a larger study at Eastern Virginia Medical School (EVMS). The 
study protocol was approved by the Institutional Review Board of EVMS (IRB#: 10-07-FB-
0135-EVMS). The purpose of this larger study is to establish a registry of data regarding 
information employed in clinical practice with patients receiving TMS for treatment of various 
psychological disorders (e.g. MDD, OCD, PTSD). At the time of this present study, the database 
contained 95 participants who have sought psychological treatment via TMS treatment regimens 
at EVMS. All participants in the database have volunteered and consented to have their treatment 
data archived (IRB#: 10-07-FB-0135; see Appendix A for registry consent form).  
 The database contained a total of 95 participants; however, after data cleaning procedures 
(see section, Data Reduction and Data Cleaning), only 68 participants were used in this study (N 
= 68). 
A-Priori Power Analysis 
 A power analysis was conducted via G*Power utilizing effect size information found in 
the literature to determine the minimum sample-size requirement for this research study. 
According to the research regarding TMS treating depressive disorders, Cohen’s d effect sizes 
range from small to medium (d = 0.35 to d = 0.76; Sabesan, et al., 2015). There is a lack of 
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information in the research body regarding the efficacy of TMS in treating cognitive 
impairments:  
…there are very limited available data in the use of these approaches [TMS] in the 
symptomatic [cognitive] treatment of dementias, the majority of trials contained 
inadequate control arms…Even in studies with positive outcomes, effect sizes have been 
small and the clinical significance of these remains to be established. (Elder & Taylor, 
2014, p 8) 
Because of this, our a-priori power analysis reflects only the treatment of depressive 
disorders (Sabesan, et al., 2015). For the power analysis, we used the smaller effect size reported 
by Sabesan and colleagues (Cohen’s d = 0.35; 2015), as the results would be more conservative. 
This d value was then converted into a ηp2 value of .030 for compatibility with the required 
G*Power procedures using formula found in Cohen (1988, p. 281-285; see Appendix B). The 
results from this power analysis indicated that our sample would need to consist of at minimum 
56 participants, with 28 participants belonging to each of our two analysis groups: (1) individuals 
meeting MCI criteria, and (2) individuals not meeting MCI criteria. While this study is 
potentially limited due to the absence of a control, or sham-TMS, group, the non-MCI group will 
serve as a useful comparison group for the MCI group, as the efficacy of TMS in treating 
depressive disorders has previously been established among individuals without MCI.  
 It is important to note that Sabesan and colleagues (2015) reviewed studies that measured 
depression using the Hamilton Depression Rating Scale (HDRS), not the Beck Depression 
Inventory II (BDI-II); however, the BDI-II demonstrates strong convergent validity with the 
HDRS, with a mean correlation of .73 and maximum correlation of up to .89 (Cusin, Yang, 
Yeung, & Fava, 2009). This strong convergent validity between the two assessments allows us to 
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generalize the effects and outcomes from the HDRS to the BDI-II for our a-priori power 
analysis. 
Instruments 
 Throughout their treatment sessions, all participants were administered a BDI-II and a 
Beck Anxiety Inventory (BAI) on a weekly basis, beginning at the start of treatment (i.e. pre-
treatment) and continuing through their final treatment session (i.e. post-treatment). Participants 
were also given three CNS-VS neurocognitive assessments throughout their treatment: one at the 
start of treatment (i.e. pre-treatment), one at week two of their treatment schedule, and one at the 
end of treatment (i.e. post-treatment).  
Beck Depression Inventory II (BDI-II). 
The BDI-II is a 21-item self-report assessment of depressive symptoms. Each item is 
ranked on a scale of 0-3 based on symptom prevalence in the last week (e.g., “Sadness” can be 
ranked 0 = I do not feel sad, 1 = I feel sad much of the time, 2 = I am sad all the time, or 3 = I 
am so sad or unhappy that I can’t stand it). 
Despite the claims made by Hyer, Sohnle, Ashraf, Hamer, and Ragan (2003), stating that 
the BDI-II and other self-report measures are not appropriate for individuals with cognitive 
impairment, the BDI-II has been utilized in studies to measure depression in both samples with 
MCI/dementia and samples without MCI/dementia while retaining adequate psychometric 
properties (Gilmartin, et al., 2015; Seidel, et al., 2015; Sinanović, Hudić, Zucić, Kapidžić, & 
Vidović, 2015). For this reason, the BDI-II was utilized for this study. 
In a study comparing young adults (n = 229, mean age = 19.6, SD = 2.2) to older adults 
(n = 147, mean age = 70.3, SD = 7.5), Segal, et al. (2015) found that the BDI-II retains adequate 
psychometric properties across the two age groups. While there did appear to be a slight decrease 
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in internal consistency from the young adult group to older adults (α = .92 and α = .86 
respectively), the findings support good internal reliability for the BDI-II among older adults.  
 The BDI-II was also found to be highly correlated with the Geriatric Depression Scale 
(GDS; r = .71), which is a previously validated measure of depression specifically for older 
adults (Segal, et al., 2008), and construct validity of the BDI-II has been thoroughly established 
within the current body of research. For example, Schroevers, Tovote, Snippe, and Fleer (2016) 
found that mindfulness is as effective as cognitive based therapy at reducing depressive 
symptoms in individuals as measured by the BDI-II. These results were congruent with their 
initial hypotheses (Schroevers, et al., 2016).  
CNS Vital Signs (CNS-VS). 
Computerized neurocognitive screening tools have a major benefit over conventional 
neurocognitive assessments: computerized assessments are more sensitive and able to detect 
MCI while in the “preclinical” phase, thus allowing for earlier detection of cognitive decline than 
conventional assessment measures, such as non-computer-based measures of gross cognitive 
functioning and dementia screening assessments (Gualtieri, 2004). In fact, “computerized 
assessment might be uniquely suited to early detection of changes in cognition in the elderly” 
(Wild, Howieson, Webbe, Seelye, & Kaye, 2008, p. 429).  
The CNS Vital Signs (CNS-VS) battery has been used in many studies to assess for MCI 
and various levels of dementia (Gualtieri, 2004; Gualtieri & Johnson, 2005; Gualtieri & Johnson, 
2006; Gualtieri & Johnson, 2008). CNS-VS results have been shown to generate differential 
profiles for individuals with MCI versus individuals with various levels of dementia (Gualtieri, 
2004). CNS-VS has been able to differentiate levels of dementia from other neurological 
disorders such as post-concussion syndrome, severe traumatic brain injuries, and ADHD. It has 
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also been shown to differentiate between MCI, dementia, and levels of depression (Gualtieri & 
Johnson, 2006), which is highly beneficial for the purposes of this study. For these reasons, 
CNS-VS was deemed an appropriate assessment tool for the context of this study. 
CNS-VS is a 30-minute, self-administered, computer-based battery used to assess 
neurocognitive performance while controlling for age and education. Seven conventional 
neuropsychological tests that span across cognitive domains that are sensitive to most causes of 
cognitive dysfunction and which are known to be reliable and valid comprise the CNS-VS 
battery (Gualtieri & Johnson, 2006).  These include: Visual Memory (visual learning and 
memory), Verbal Memory (verbal learning and memory), Finger Tapping (motor speed), Symbol 
Digit Coding (information processing and visual-perceptual speed), Stroop Test (executive 
function), Shifting Attention Test (executive function), and Continuous Performance Test 
(sustained attention).  From these 7 tests, domain scores in the following 10 categories are 
produced: Neurocognition Index, Composite Memory, Verbal Memory, Visual Memory, 
Processing Speed, Executive Function, Psychomotor Speed, Reaction Time, Complex Attention, 
and Cognitive Flexibility (CNS Vital Signs, LLC, 2003).  
Studies have produced support for strong reliability with test-retest coefficients ranging 
from 0.65 to 0.88. Convergent validity comparing the CNS-VS to conventional 
neuropsychological assessments has been established, with moderate correlations between the 
CNS-VS and: the Neurobehavioral Evaluation System II (NES2) ranging from r = .30 to r = .60; 
Rey Auditory Verbal Learning Test ranging from r = .49 to r = .56; Logical Memory and Facial 
Recognition subtests of the Wechsler Memory Test ranging from r = .35 to r = .56; mechanical 
finger tapping ranging from r = .13 to r = .26; Stroop Test with r = .51; Trails B with r = .45; and 
the Verbal Fluency Test with r = .45 (Gualtieri & Johnson, 2006). While many of these 
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correlations are moderate in magnitude, it is important to note that many of them may have been 
attenuated by the lack of common method variance, as many of these are not computerized 
assessments.  
According to Kelly and Peterson (2007), “MCI subjects tend to fall 1.5 standard 
deviations below their age- and education-matched peers on measurements of learning and 
recall” (p. 582). It is also noted that these are “guidelines and not cutoff scores for assisting in the 
diagnosis of MCI” (p. 582). Saykin and Rabin (2014) also stated that MCI can be operationalized 
as “…decline in neurocognitive test performance, typically between one and two standard 
deviations below appropriate norms, or 3rd-16th percentile” (p. 240). Regardless of cognitive 
decline, a key component of MCI is that independence through activities of daily living (ADLs) 
is typically preserved, even though the use of compensatory strategies and increased effort are 
often noted (Saykin & Rabin, 2014).   
Peterson (2013) defined MCI as the presence of cognitive decline measured in a single 
cognitive domain while independence is preserved. When multiple cognitive domains show 
significant impairment and loss of independence is noted, a diagnosis of dementia, or MND, is 
more appropriate. Declines in cognitive domains can be assessed in many ways: formal and 
informal assessments of the individual providing the complaint, informal assessments of 
reputable sources close to the individual in question, and computerized cognitive batteries 
(Peterson, 2013; Saykin & Rabin, 2014).  
MCI is typically categorized into two subtypes: amnestic MCI and non-amnestic MCI, 
which are defined as cognitive impairments with the presence or absence of memory 
impairments respectively (Peterson, 2007). Even further, both amnestic MCI and non-amnestic 
MCI can be further defined as single-domain and multiple-domain. While MCI usually appears 
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with only one major cognitive domain (outside of memory complaints) impaired, it is possible to 
find cases of MCI in which multiple domains are impaired (Peterson, 2007), as long as 
independence and ADL ability are still widely maintained (Peterson, 2007; Peterson, 2013; 
Saykin & Rabin, 2014). These findings have also been established in a report by the Alzheimer’s 
Association in defining the clinical diagnosis of MCI (Albert, et al., 2010).  
Because it appears that no one specific cognitive domain is impaired across MCI 
diagnoses, with the exception of memory in amnestic-MCI, the operationalization of MCI for the 
purpose of this study was as follows: CNS-VS scores indicating an individual being at least one 
standard deviation below their age- and education-based norms on at least one cognitive domain. 
To increase the power of this study, amnestic and non-amnestic MCI were defined separately in 
the analyses. The CNS-VS was then used to track cognitive changes throughout treatment among 
the two groups: (1) participants meeting MCI criteria and (2) participants not meeting MCI 
criteria. This methodology is supported by Harvey (2012): “It makes sense that the same 
measures of cognitive functioning used to identify functionally relevant deficits across different 
neuropsychiatric conditions would be used to measure treatment outcomes” (p. 96).  
Beck Anxiety Inventory (BAI). 
The Beck Anxiety Inventory (BAI) was used in this study as a means of measuring and 
covarying anxiety from our statistical model, as depression and anxiety are positively correlated 
when measured together (r > .50; Beck, Epstein, Brown, & Steer, 1988, p. 893). The BAI is a 
21-item self-report measure designed to assess for anxiety, with each item being scored on a 4-
point scale based on the prevalence of specific anxiety-related symptoms within the last week 
(e.g., “Nervousness” can be ranked 0 = Not at All; 1 = Mildly; 2 = Moderately; 3 = Severely).  
The BAI has demonstrated good test-retest reliability, with r = .75, and sound internal 
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consistency, with Cronbach’s α = .92 (Beck, Ebstein, Brown, & Steer, 1988, p. 895). Convergent 
validity of the BAI has been established with the Hamilton Anxiety Rating Scale, a previously 
established measure of anxiety, with coefficients ranging from .47 to .58 (Grant, n.d., p. 2). The 
construct validity of the BAI has been well established in the literature. For example, Potes, 
Gagnon, Touré, and Perreault (2016) found that psychoeducational programs improve symptoms 
of anxiety among individuals. These results were congruent with their initial hypotheses (Potes, 
et al., 2016). 
No studies could be found assessing the psychometric properties of the BAI among 
cognitively impaired populations. However, the BAI has been used to assess anxiety among 
geriatric populations, age 60 years and older, and it has remained psychometrically sound. Test-
retest coefficients among geriatric individuals ranged from .62 (seven-week interval) to .93 (one-
week interval), and Cronbach’s α ranged from .90 to .94 (Potes, et al., 2016, p. 653). It should be 
noted that this study by Potes, and colleagues (2016) excluded individuals with MCI, assessed by 
scores less than 28 on the Mini-Mental Status Exam (MMSE).  
Procedures 
 Individuals seeking treatment in the Eastern Virginia Medical School (EVMS) TMS 
program underwent 36 treatment sessions. Each session lasted approximately 40 minutes and 
occurred five days per week for six weeks, followed by a three-week taper which spaced out the 
remaining sessions over the three-week period (e.g., three TMS sessions during the seventh 
week, two sessions during the eighth week, and one session during the ninth week). Individuals 
may receive extra TMS sessions, deemed “maintenance sessions,” if needed after the initial 
treatment schedule. For the scope of this study, we focused on the 36 initial sessions only.  
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 All participants in the EVMS TMS treatment program were evaluated for the presence of 
treatment-resistant, or refractory, depression. Depressive disorder diagnoses are deemed 
treatment-resistant when antidepressant medications in adequate doses/intensities trialed over 
sufficient time to produce treatment responses have failed to produce remission in depressive 
symptoms (Chappell, 2016). To date, ECT has been the primary treatment modality for 
treatment-resistant depression; however, there appears to be considerable research consensus that 
TMS/rTMS is not only equally efficacious in comparison to ECT, but also more cost-effective, 
patient-preferred, and less risky (Magnezi, et al., 2016; U.S. DHHS, FDA, & CDRH, 2011). 
 Prior to the first TMS treatment session, the patient’s resting motor threshold (RMT) was 
established to ensure precision of stimulation. RMTs were determined by applying single 
magnetic pulses over the right motor cortex area until a twitch in the contralateral hand was 
achieved. Participants over the age of 70 also underwent neuroimaging procedures in order to 
measure any cortical atrophy.  
 Upon intake, participants were evaluated for the presence of depressive disorders and/or 
anxiety disorders. Individuals with only depressive disorders (e.g., major depressive disorder 
without anxious features) were assigned to the left TMS protocol. Individuals with depressive 
disorders and clinically elevated levels of anxiety were assigned to the right TMS protocol. The 
left protocol targeted the left dorsolateral prefrontal cortex (LDLPFC), and it is widely 
considered the most commonly used location for stimulation in TMS when treating depressive 
disorders only (Herbsman, et al., 2009; Teng, et al., 2017). Studies using EEGs to measure brain 
activity among individuals with major depressive disorder have revealed asymmetrical activity 
levels in the DLPFC (Ricardo-Garcell, et al., 2009). TMS studies targeting both the right and the 
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left DLPFC have produced positive outcomes in reducing depressive symptomology (Teng, et 
al., 2017). 
The right protocol targeted the right dorsolateral prefrontal cortex (RDLPFC) as well as 
the right supplementary motor area (SMA), and it is primarily used for individuals with 
depressive disorders as well as clinically elevated levels of anxiety, history of trauma, or 
obsessive-compulsions. Similar to the LDLPFC, stimulating the RDLPFC is also associated with 
improvements in depressive symptomology (Luber, et al., 2017). The right SMA has been 
studied with TMS in managing anxiety-related symptoms (e.g., anxiety disorders, PTSD, and 
OCD; Fontenelle, Nascimento, Mendlowicz, Shavitt, & Versiani, 2007; Machado, et al., 2013; 
Mantovani, n.d.; Mantovani, Simpson, Fallon, Rossi, & Lisanby, 2010), treating cognitive 
impairments and depressive symptoms among individuals with VaD with successful outcomes 
(Pennisi, et al., 2016), as well as specifically improving visual-spatial processing (Cona, Marino, 
& Semenza, 2017). 
 Individuals who received the right TMS protocol received 1,200 pulses at 1Hz, 110% 
RMT to the RDLPFC for 20 minutes and 8 seconds and 1,200 pulses at 1Hz, 100% RMT to the 
right SMA for 20 minutes and 8 seconds, with stimulations being delivered in 1-second pulses at 
each area for a total duration of 40 minutes and 16 seconds each session. Individuals who 
received the left TMS protocol received 3,000 pulses at between 5 and 20 Hz, 120% RMT to the 
LDLPFC, with stimulations being delivered 10 pulses per second for four seconds with a 26-
second pause in stimulation for each train of pulses, totaling to 37 minutes and 40 seconds each 
session.  
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During their treatment schedules, participants complete the BDI-II and BAI once per 
week, including pre- and post-treatment measurements. The CNS-VS is administered three times 
during the treatment schedule: pre-treatment, two weeks into treatment, and post-treatment. 
Design and Statistical Analysis 
 The effects of TMS on depressive symptomology and neurocognitive performance were 
evaluated over time. Treatment data was taken from multiple time-points during the treatment 
schedule: pre-treatment, week two of treatment, and post-treatment. Utilizing multiple time 
points also reduced the risk of regression toward the mean. 
The statistical analysis procedures for this study consisted of the following: (1) a repeated 
measures split-plot ANOVA (time: baseline, two weeks, post-treatment; cognitive function 
groups: 0 = MCI, 1 = non-MCI) on BDI-II scores. This would show changes in depression levels 
across time, and if these differences over time are different between the two cognitive function 
groups; (2) a series of repeated measures split-plot ANOVA (time: baseline, two weeks, post-
treatment; cognitive function groups: 0 = MCI, 1 = non-MCI) on CNS-VS scores, which would 
show cognitive changes among individuals with cognitive impairment versus individuals without 
cognitive impairment over time; (3) a regression model regressing the CNS-VS scores onto the 
BDI-II scores. The residual values from this regression model represented the CNS-VS scores 
while holding depression (BDI-II scores) constant; and (4) a third series of repeated measures 
split-plot ANOVA (time: baseline, two weeks, post-treatment; cognitive function groups: 0 = 
MCI, 1 = non-MCI) on the residual CNS-VS values from the above regression analysis. This 
would show cognitive changes as a result of TMS treatment above and beyond any depression 
changes.  
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IRB Submissions 
 This study was submitted to the Institutional Review Boards (IRBs) of both Eastern 
Virginia Medical School (EVMS) and Old Dominion University (ODU). EVMS served as the 
primary reviewer, as the data was being extracted from a previously approved registry database 
created and maintained at EVMS. EVMS approved the study on January 16, 2018 (IRB 
Approval #: 17-12-WC-0293-EVMS). ODU subsequently approved this research study on 
February 6, 2018 (IRB Approval #: 1184323-1). 
Results 
Data Reduction and Data Cleaning 
 The registry database contained a total of 95 participants. For the purpose of this study, 
though, participants were excluded from the analyses if they met any of the following criteria: 
(1) they did not initiate or complete their course of treatment, (2) they did not have a diagnosis of 
MDD at the time of referral, or (3) they were not diagnosed with MDD during the pre-treatment 
evaluations. Of the 95 total participants, five received an initial evaluation but did not initiate 
treatment. An additional 12 participants started TMS treatment but did not complete the entire 36 
treatment sessions. Of the remaining participants who completed treatment, 10 did not have a 
primary diagnosis of MDD, nor were they diagnosed with MDD at the initial evaluations. As a 
result, 27 total participants were excluded from this research study, leaving a total sample of 68 
participants (N = 68). 
 Participants were then classified as either meeting MCI criteria (0) or not meeting MCI 
criteria (1). Of the 68 participants included in this study, 38 met the previously outlined MCI 
criteria (i.e. baseline CNS-VS scores indicating below average performance on at least one 
cognitive domain) and 30 did not meet MCI criteria (i.e. baseline CNS-VS scores indicating all 
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cognitive domains at least within average range). Based on the results from the a-priori power 
analysis, this research study does meet pre-determined sample-size criteria for statistical power.  
 Each dependent variable was screened for skewness and kurtosis statistics in order to 
assess the ANOVA assumption of normality. According to Skeskin (2011), both skewness and 
kurtosis statistics are considered within normal limits if their absolute value is less than 1.96; as a 
result, this benchmark was used to assess normality of distribution in the dependent variables. 
Table 1 shows the skewness and kurtosis statistics of each dependent variable. Based on these 
results, many of the dependent variables did not meet criteria for normal distribution.  
 
 
Table 1 
Skewness and Kurtosis Statistics 
Variable Name N Skewness Kurtosis 
BDI-II Baseline 68 -0.37 -0.27 
BDI-II Week 2 68 0.24 -0.78 
BDI-II End-of-Treatment 68 0.69 -0.84 
CNS-VS Neurocognition Index, Baseline 68 -1.79 4.11 
CNS-VS Composite Memory, Baseline 68 -0.64 0.73 
CNS-VS Verbal Memory, Baseline 68 -0.73 0.03 
CNS-VS Visual Memory, Baseline 68 -0.40 -0.26 
CNS-VS Processing Speed, Baseline 68 0.07 0.93 
CNS-VS Executive Functioning, Baseline 68 -1.53 3.40 
CNS-VS Psychomotor Speed, Baseline 68 -0.79 3.82 
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CNS-VS Reaction Time, Baseline 68 -0.16 2.32 
CNS-VS Complex Attention, Baseline 68 -4.53 26.60 
CNS-VS Cognitive Flexibility, Baseline 68 -1.46 2.83 
CNS-VS Neurocognition Index, Week 2 68 -1.22 2.18 
CNS-VS Composite Memory, Week 2 68 -0.44 0.70 
CNS-VS Verbal Memory, Week 2 68 -0.60 -0.20 
CNS-VS Visual Memory, Week 2 68 -0.31 0.21 
CNS-VS Processing Speed, Week 2 68 0.18 -0.32 
CNS-VS Executive Functioning, Week 2 68 -1.55 3.49 
CNS-VS Psychomotor Speed, Week 2 68 -0.09 2.15 
CNS-VS Reaction Time, Week 2 68 -0.52 16.02 
CNS-VS Complex Attention, Week 2 68 -3.74 2.61 
CNS-VS Cognitive Flexibility, Week 2 68 -1.40 6.99 
CNS-VS Neurocognition Index, End-of-Treatment 68 -1.85 1.43 
CNS-VS Composite Memory, End-of-Treatment 68 -0.87 2.96 
CNS-VS Verbal Memory, End-of-Treatment 68 -1.41 -0.53 
CNS-VS Visual Memory, End-of-Treatment 68 -0.09 2.57 
CNS-VS Processing Speed, End-of-Treatment 68 -1.04 11.44 
CNS-VS Executive Functioning, End-of-Treatment 68 -2.48 2.00 
CNS-VS Psychomotor Speed, End-of-Treatment 68 0.33 2.35 
CNS-VS Reaction Time, End-of-Treatment 68 -1.24 10.67 
CNS-VS Complex Attention, End-of-Treatment 68 -3.14 10.47 
CNS-VS Cognitive Flexibility, End-of-Treatment 68 -2.44 -0.27 
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 Analysis of the data, via box-plots and interquartile range calculations, showed a 
significant number of outliers. While no multivariate outliers were detected within the data, 
many univariate outliers were present. This likely influenced the distribution of the data, leading 
to the extreme skewness/kurtosis values seen in Table 1. According to Jamaluddin, Abdullah, 
and Yahaya (2014), winsorization of extreme outliers is an appropriate approach to managing 
univariate outliers, especially when they are causing non-normality in variable distributions. 
Based on this information, the winsorization approach was used to treat univariate outliers in the 
dependent variable data. After winsorization, all variables fell within normal limits in both 
skewness and kurtosis values (i.e. below absolute value of 1.96; Skeskin, 2011). Typical 
procedures dictate that data analyses should be run both before and after correction of outliers; 
however, because the normality of variables was violated to such an extreme level before 
treating for outliers, data analyses would not be reliable; as a result, the data were only analyzed 
after treating for outliers. All other ANOVA assumptions were met. 
Sample Demographics  
 All participants in this research study (N = 68) completed TMS treatment. Participants 
were separated into two groups (MCI and non-MCI) based on the pre-determined criteria. 
Demographic information was obtained for each group in the following areas: age, baseline BAI 
score, baseline BDI-II score, type of TMS protocol, and education level. Analyses were run on 
the demographics variables to determine any significant differences between the MCI and non-
MCI groups: age differences were nonsignificant, with t(66) = 1.61, p = .113 (see Table 2); sex 
differences were nonsignificant, with χ2(1) = 0.21, p = .649 (see Table 2); baseline BAI scores 
were nonsignificant, with t(66) = 0.87, p = .388 (see Table 2); baseline BDI-II scores were 
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nonsignificant, with t(66) = 1.12, p = .268 (see Table 2); type of TMS protocol between groups 
was nonsignificant, with χ2(1) = 2.38, p = .123 (see Table 2); and education level between groups 
was nonsignificant, with χ2(7) = 5.23, p = .608 (see Table 2). Because these variables were not 
significantly different between the groups, there was no empirical rationale to use them as 
covariates in the statistical model. As such, these variables will not be used as covariates in this 
study.  
 
 
Table 2 
Demographic Information by Group 
  N Mean SD 
MCI Age 38 47.76 14.03 
 Baseline BAI Scores 38 18.45 11.84 
 Baseline BDI-II Scores 38 34.71 12.17 
Non-MCI Age 30 42.17 14.52 
 Baseline BAI Scores 30 21.70 12.05 
 Baseline BDI-II Scores 30 37.00 8.74 
Total Age 68 45.29 14.41 
 Baseline BAI Scores 68 19.88 11.92 
 Baseline BDI-II Scores 68 35.72 10.78 
 N (%)   
 Left TMS Protocol Right TMS Protocol   Total N (%)  
MCI 11 (16.18) 27 (39.71) 38 (55.88)  
Non-MCI 4 (5.88) 26 (38.24) 30 (44.12)  
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Total 15 (22.06) 53 (77.94) 68 (100.00)  
  N %  
MCI Males 16 23.53  
 Females 22 32.35  
 Total (sex) 38 55.88  
 High School / GED 7 10.61  
 Some College 7 10.61  
 Trade School / Certificate 1 1.52  
 2-Year College Degree 5 7.58  
 4-Year College Degree 7 10.61  
 Master’s Degree 7 10.61  
 Doctoral Degree 1 1.52  
 Professional Degree (MD, JD) 1 1.52  
 Total (edu) 36 54.55  
Non-MCI Males 11 16.18  
 Females 19 27.94  
 Total (sex) 30 44.12  
 High School / GED 3 4.55  
 Some College 7 10.61  
 Trade School / Certificate 0 0.00  
 2-Year College Degree 2 3.03  
 4-Year College Degree 11 16.67  
 Master’s Degree 4 6.06  
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 Doctoral Degree 2 3.03  
 Professional Degree (MD, JD) 1 1.52  
 Total (edu) 30 45.45  
Total Males 27 39.71  
 Females 41 60.29  
 Total (sex) 68 100.00  
 High School / GED 10 15.15  
 Some College 14 21.21  
 Trade School / Certificate 1 1.52  
 2-Year College Degree 7 10.61  
 4-Year College Degree 18 27.27  
 Master’s Degree 11 16.67  
 Doctoral Degree 3 4.55  
 Professional Degree (MD, JD) 2 3.03  
 Total (edu) 66 100.00  
 
 
 
Reliability of Measures 
 Reliability via internal consistency (Cronbach’s α) of the BDI-II and the BAI was 
assessed at each time point (baseline, week two, end-of-treatment). The BDI-II demonstrated 
strong internal consistency at all time points in the total sample, with baseline α = .89, week two 
α = .92, and end-of treatment α = .96. The BAI also demonstrated strong internal consistency 
across all time points in the total sample, with baseline α = .91, week two α = .93, and end-of-
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treatment α = .95. Both measures also demonstrated strong internal consistency within the MCI 
group, with BDI-II baseline α = .91, week two α = .92, and end-of-treatment α = .95, and BAI 
baseline α = .87, week two α = .92, and end-of-treatment α = .92. For the non-MCI group, 
internal consistency statistics were good-to-strong, with BDI-II baseline α = .77, week two α = 
.86, and end-of-treatment α = .95, and BAI baseline α = .92, week two α = .92, and end-of-
treatment α = .96. 
Research Question 1 
 The first research question investigated in this study was as follows: can TMS be used 
effectively to treat depression in patients with MCI? The resulting hypothesis was that TMS 
treatment will improve depression levels significantly among individuals meeting MCI criteria, 
and that any improvements here will not be significantly different from improvements seen in the 
non-MCI group – in other words, TMS treatment should be equally effective for both the MCI 
and non-MCI groups.  
 This hypothesis was tested using a repeated measures split-plot ANOVA (time: baseline, 
two weeks, post-treatment; cognitive function groups: 0 = MCI, 1 = non-MCI) on BDI-II scores 
in order to show any treatment differences between the cognitive function groups on depression. 
Familywise alpha was set to .05 and did not need further correction, as this ANOVA falls under 
its own family of tests.  
Sphericity could not be assumed, with Mauchly’s χ2(2) = 17.05, p < .001. As a result, 
Greenhous-Geisser’s correction of sphericity was used, with Ɛ̂ = .81. Greenhouse-Geisser’s 
correction was chosen over Huynh-Feldt as it is a more conservative correction of sphericity than 
Hyunh-Feldt. The treatment/time effect showed significant changes in depressive symptoms 
from start-to-end of treatment, with F(1.63, 107.26) = 77.41, p < .001, ηp2 = .540 (see Figure 1). 
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Post-hoc pairwise comparisons between each time interval (baseline, week two, end of 
treatment) were performed using Bonferroni comparisons. Type 1 error (alpha) was corrected 
here using Bonferroni’s alpha correction formula, αPC = α/C (Maxwell & Delaney, 2004, p. 202), 
where α = .05 and C = 3. The resulting alpha per contrast resulted: αPC = .0167. The following 
follow-up pairwise comparisons were significant at the corrected αPC: baseline-to-week-two, 
with MD = 13.26, SE = 1.27, p < .001, 95% CI [10.14, 16.38]; baseline-to-end-of-treatment, with 
MD = 18.78, SE = 1.88, p < .001, 95% CI [14.17, 23.40]; and week-two-to-end-of-treatment, 
with MD = 5.53, SE = 1.44 p = .001, 95% CI [1.99, 9.07]. The group-by-time differences were 
not significant, with F(1.63, 107.26) = 0.27, p = .721, ηp2 = .004 (see Figure 1), indicating no 
significant differences between the MCI and non-MCI groups on depressive symptom 
improvement. 
 
 
 
Figure 1. Depressive Symptom Improvement (BDI-II) between MCI and Non-MCI Groups 
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Research Question 2 
 The second research question investigated in this study was as follows: can TMS be used 
to improve cognitive functioning among individuals with MCI independent of mood 
improvements? The resulting hypothesis was that TMS treatment will produce significant 
improvements in neurocognitive functioning among individuals with MCI, and that these 
improvements will remain significant after controlling for the variance of improvements in 
depressive symptoms.   
 This hypothesis was tested using multiple repeated measures split-plot ANOVAs (time: 
baseline, two weeks, post-treatment; cognitive function groups: 0 = MCI, 1 = non-MCI) on CNS-
VS domain scores in order to show any treatment differences among different neurocognitive 
domains. Familywise error was set at .05. Given that 10 repeated measures split-plot ANOVAs 
were performed (one for each neurocognitive domain dependent variable), error per comparison 
was corrected using Bonferroni’s alpha correction formula, αPC = α/C (Maxwell & Delaney, 
2004, p. 202), where α = .05 and C = 10. The resulting alpha per contrast resulted: αPC = .005. 
Where significant treatment/time effects were found, post-hoc pairwise comparisons were 
analyzed using Bonferroni comparisons, and the Type 1 error rate was corrected further, with 
Bonferroni’s alpha correction formula, αPC = α/C (Maxwell & Delaney, 2004, p. 202), where α = 
.005 and C = 3. The resulting corrected error per contrast was αPC = .0017. In any situations in 
which sphericity could not be assumed, Greenhous-Geisser’s correction of sphericity was used, 
as it is the more conservative correction method. 
 For Neurocognition Index (NCI), sphericity could not be assumed, with χ2(2) = 13.01, p 
= .001, with Ɛ̂ = .85. The treatment/time effect was significant, with F(1.69, 111.74) = 20.14, p < 
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.001, ηp2 = .234. The group-by-time was also significant, with F(1.69, 111.74) = 8.34, p = .001, 
ηp2 = .112, indicating a difference MCI and non-MCI groups on NCI (see Figure 2).  
 
 
 
Figure 2. Neurocognition Index Improvement between MCI and non-MCI Groups 
 
 
For Composite Memory (CM), sphericity was assumed, with χ2(2) = 1.19, p = .551. The 
treatment/time effect on CM changes was not significant, with F(2, 132) = 1.87, p = .158, ηp2 = 
.028 (see Figure 3). For Verbal Memory (VERM), sphericity was assumed, with χ2(2) = 5.82, p 
= .055. The treatment/time effect on VERM changes was not significant, with F(2, 132) = 3.06, 
p = .050, ηp2 = .044 (see Figure 4). For Visual Memory (VISM), sphericity was assumed, with 
χ2(2) = .54, p = .765. The treatment/time effect on VISM changes was not significant, with F(2, 
132) = .72, p = .487, ηp2 = .011 (see Figure 5). No further follow-up tests for CM, VERM, or 
VISM were performed. 
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Figure 3. Composite Memory Improvement between MCI and Non-MCI Groups 
 
 
 
Figure 4. Verbal Memory Improvement between MCI and Non-MCI Groups 
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Figure 5. Visual Memory Improvement between MCI and Non-MCI Groups 
 
 
For Processing Speed (PROSS), sphericity could not be assumed, with χ2(2) = 7.03, p = 
.030, with Ɛ̂ = .91. The treatment/time effect was significant, with F(1.81, 119.73) = 20.21, p < 
.001, ηp2 = .234. The group-by-time was not significant, with F(1.81, 119.73) = 1.22, p = .297, 
ηp2 = .018, indicating no difference MCI and non-MCI groups on PROSS changes (see Figure 6).  
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Figure 6. Processing Speed Improvement between MCI and Non-MCI Groups 
 
 
For Executive Function (EF), sphericity could not be assumed, with χ2(2) = 9.30, p = 
.010, with Ɛ̂ = .88. The treatment/time effect was significant, with F(1.77, 116.47) = 26.82, p < 
.001, ηp2 = .289. The group-by-time was significant, with F(1.77, 116.47) = 7.96, p = .001, ηp2 = 
.108, indicating a significant difference between MCI and non-MCI groups on EF changes (see 
Figure 7).  
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Figure 7. Executive Function Improvement between MCI and Non-MCI Groups 
 
 
For Psychomotor Speed (PSYS), sphericity could not be assumed, with χ2(2) = 9.32, p = 
.009. with Ɛ̂ = .88. The treatment/time effect was significant, with F(1.76, 116.44) = 18.68, p < 
.001, ηp2 = .221. The group-by-time was not significant, with F(1.76, 116.44) = 0.61, p = .524, 
ηp2 = .009, indicating no difference in treatment progression between MCI and non-MCI groups 
(see Figure 8).  
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Figure 8. Psychomotor Speed Improvement between MCI and Non-MCI Groups 
 
 
For Reaction Time (RT), sphericity was assumed, with χ2(2) = 5.16, p = .076. The 
treatment/time effect was not significant, with F(2, 132) = 1.14, p = .323, ηp2 = .017. No further 
follow-up testing for RT was performed (see Figure 9). 
 
 
 
Figure 9. Reaction Time Improvements between MCI and Non-MCI Groups 
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For Complex Attention (CA), sphericity could not be assumed, with χ2(2) = 11.75, p = 
.003, with Ɛ̂ = .86. The treatment/time effect was significant, with F(1.72, 113.27) = 15.57, p < 
.001, ηp2 = .191. The group-by-time was significant, with F(1.72, 113.27) = 10.96, p < .001, ηp2 = 
.142, indicating a significant difference in treatment progression between MCI and non-MCI 
groups (see Figure 10).  
 
 
 
Figure 10. Complex Attention Improvement between MCI and Non-MCI Groups 
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.013, with Ɛ̂ = .89. The treatment/time effect was significant, with F(1.78, 117.41) = 28.43, p < 
.001, ηp2 = .301. The group-by-time was significant, with F(1.78, 117.41) = 8.71, p = .001, ηp2 = 
.117, indicating a significant difference in treatment progression between MCI and non-MCI 
groups (see Figure 11). 
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Figure 11. Cognitive Flexibility Improvement between MCI and Non-MCI Groups 
 
 
Table 3 
ANOVAs: TMS on Neurocognitive Performance between MCI and Non-MCI Groups 
  df Mean Square F ηp2 
NCI TMS Treatment Over Time 1.69 16363.75 20.14** .234 
 Group X Time 1.69 677.55 8.34* .112 
 Error 111.74 81.25   
CM TMS Treatment Over Time 2 246.84 1.87 .028 
 Group X Time 2 397.54 3.02 .044 
 Error 132 131.69   
VERM TMS Treatment Over Time 2 498.52 3.06 .044 
 Group X Time 2 268.99 1.65 .024 
 Error 132 132.98   
VISM TMS Treatment Over Time 2 108.30 0.72 .011 
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 Group X Time 2 254.42 1.70 .025 
 Error 132 148.56   
PROSS TMS Treatment Over Time 1.81 1690.17 20.21** .234 
 Group X Time 1.81 101.83 1.22 .018 
 Error 119.73 83.63   
EF TMS Treatment Over Time 1.77 3570.43 26.82** .289 
 Group X Time 1.77 1059.65 7.96* .108 
 Error 116.47 133.12   
PSYS TMS Treatment Over Time 1.76 1934.20 18.68** .221 
 Group X Time 1.76 63.36 0.61 .009 
 Error 116.40 103.57   
RT TMS Treatment Over Time 2 98.32 1.14 .017 
 Group X Time 2 10.77 0.13 .002 
 Error 132 86.36   
CA TMS Treatment Over Time 1.72 5117.20 15.57** .191 
 Group X Time 1.72 3602.87 10.96** .142 
 Error 113.27 328.68   
CF TMS Treatment Over Time 1.78 3959.18 28.43** .301 
 Group X Time 1.78 1212.13 8.71* .117 
 Error 117.41 139.25   
* p < .005 (corrected error rate, Bonferroni) 
** p < .001 
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Table 4 
Significant Post-Hoc Pairwise Comparisons among Significant CNS-VS Domain Improvements 
     95% CI 
   MD SE Lower 
Bound 
Upper 
Bound 
NCI Baseline Week 2 -6.02** 1.25 -9.09 -2.95 
  End of Treatment -8.91** 1.71 -13.11 -4.71 
PROSS Baseline Week 2 -7.18** 1.34 -10.48 -3.89 
  End of Treatment -9.06** 1.73 -13.30 -4.82 
EF Baseline Week 2 -9.20** 1.76 -13.51 -4.89 
  End of Treatment -13.40** 2.18 -18.76 -8.04 
PSYS Baseline Week 2 -8.10** 1.64 -12.12 -4.08 
  End of Treatment -9.26** 1.90 -13.92 -4.59 
CA Baseline Week 2 -10.37** 2.79 -17.22 -3.51 
  End of Treatment -15.95** 3.41 -24.33 -7.57 
CF Baseline Week 2 -9.59** 1.82 -14.06 -5.13 
  End of Treatment -14.21** 2.23 -19.68 -8.73 
*p < .0017 (corrected error rate, Bonferroni) 
**p < .001  
 
 
In order to remove the variance of depressive symptom improvements from CNS-VS 
neurocognitive domain variables at each time point, each CNS-VS neurocognitive domain was 
regressed onto the BDI-II score at the same time point (example: baseline NCI score was 
regressed onto baseline BDI-II score; week two NCI score was regressed onto week two BDI-II 
45 
 
score; end-of-treatment NCI score was regressed onto end-of-treatment BDI-II score). The 
residual values from these regressions were saved as new variables, as their values represented 
changes in neurocognitive performance across TMS treatment intervals independent of changes 
in depressive symptoms. Those new variables were then used as the dependent variables in 
another series of repeated measures split-plot ANOVAs (time: baseline, two weeks, post-
treatment; cognitive function groups: 0 = MCI, 1 = non-MCI) on the new CNS-VS domain 
variable independent of BDI-II scores. In order to prevent the error rate from being compounded 
more than necessary, only the CNS-VS neurocognitive domains that displayed significant 
improvement earlier were included in these analyses: NCI, PROSS, EF, PSYS, CA, and CF.  
Type 1 error rate had to be corrected even further for these analyses. The new further-
corrected error rate was determined using Bonferroni’s alpha correction formula, αPC = α/C 
(Maxwell & Delaney, 2004, p. 202), where α = .005 and C = 6. The resulting corrected error per 
contrast was αPC = .0008. If any significant results were found here, post-hoc pairwise 
Bonferroni comparisons were examined. Type 1 error rate was corrected again using 
Bonferroni’s alpha correction formula, αPC = α/C (Maxwell & Delaney, 2004, p. 202), where α = 
.0008 and C = 3. The resulting corrected error per contrast was αPC = .0003. For instances in 
which sphericity could not be assumed, Greenhouse-Geisser’s sphericity correction was used, as 
it is the more conservative correction of sphericity. None of these analyses showed significant 
results (see Table 5), indicating any potential treatment improvements in neurocognitive 
functioning as a result of TMS treatment occur as a function of TMS treating depressive 
symptoms.  
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Table 5 
ANOVAs: TMS on Neurocognitive Performance Independent of Depressive Symptom Changes 
  Ɛ̂ df Mean Square F ηp2 
NCI TMS Treatment Over Time .88 1.76 0.01 0.04 .001 
 Error .88 116.33 0.34   
PROSS TMS Treatment Over Time - 2 0.01 0.03 <.001 
 Error - 132 0.22   
EF TMS Treatment Over Time - 2 0.01 0.02 <.001 
 Error - 132 0.36   
PSYS TMS Treatment Over Time .87 1.74 0.004 0.02 <.001 
 Error .87 114.93 0.27   
CA TMS Treatment Over Time .88 1.76 0.02 0.04 .001 
 Error .88 116.17 0.44   
CF TMS Treatment Over Time - 2 0.01 0.02 <.001 
 Error - 132 0.32   
* p < .0008 (corrected error rate, Bonferroni) 
 
 
Discussion 
 TMS is a previously established treatment for treatment-resistant, or refractory, 
depression; however, its efficacy has not been established in treating depression among 
individuals diagnosed with MCI. Prior research indicates that MCI and depression are not only 
comorbid, but depression is likely a prodromal factor to the onset of MCI/dementia. While 
depression and MCI are two separate disorders, research has shown the two disorders to be 
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strongly linked. The aim of this research study was to determine (1) if TMS can be an efficacious 
treatment for depression among individuals diagnosed with MCI and (2) if TMS can improve 
neurocognitive functioning independent of any improvements in depressive symptoms. Based on 
the current body of research, two hypotheses were generated: (1) TMS will be equally 
efficacious in treating depressive symptoms for individuals with MCI and individuals without 
MCI; (2) TMS will create significant improvements among neurocognitive functioning, and 
these improvements will remain significant independent of depressive symptom improvement. 
 The results of this study indicate that TMS can be an efficacious treatment for depression 
among individuals with MCI. Both the MCI group and non-MCI group experienced significant 
reduction in depressive symptoms across TMS treatment at all three time points. It is also 
important to note that the two groups did not differ significantly in their treatment progression, 
indicating that the MCI group experienced depressive symptom reduction at a statistically similar 
rate to the non-MCI group. As a result, these results allow for a rejection of the null hypothesis, 
and therefore provide empirical support that TMS may be equally efficacious in treating 
depression among individuals diagnosed with MCI compared to those of average neurocognitive 
functioning. While this study appears to be the first empirical examination of comparative 
efficacy between MCI and non-MCI groups, the results are consistent with hypotheses presented 
in the literature. Previous research has indicated that TMS can create significant changes in 
cortical excitability and neuroplasticity among individuals with MCI/dementia (Alberici, et al., 
2008; Elder & Taylor, 2014; Issac, Chandra, & Nagaruju, 2013; Luber & Lisanby, 2014; 
Nardone, et al., 2015; Pennisi, et al., 2006), which provides support for the prediction of TMS as 
an efficacious treatment method for individuals with MCI. Given the current body of research, in 
conjunction with the results of this current study, TMS appears to produce changes in cortical 
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excitability and neuroplasticity, and in turn, significant improvements in depressive symptoms, 
for individuals with MCI at a statistically similar level to individuals with average 
neurocognitive functioning. In other words, TMS appears to be equally efficacious in treating 
depressive symptoms for individuals with lower levels of cognitive function and individuals with 
average levels of cognitive function.   
 With regards to the second hypothesis, the results indicated significant improvements in 
neurocognitive functioning across some CNS-VS domains, but not all. TMS treatment appears to 
produce significant improvements in gross neurocognition index, processing speed, executive 
function, psychomotor speed, complex attention, and cognitive flexibility. However, composite 
memory, verbal memory, visual memory, and reaction time did not improve significantly 
throughout the duration of TMS treatment. Further analyses revealed that any significant 
improvements in neurocognitive domains did not remain significant after controlling for the 
variance of depressive symptom improvement, indicating that while TMS alone may improve 
neurocognitive functioning, it does so as a function of treating depressive symptoms. As a result, 
the null hypothesis could not be rejected. At first glance, results appear to contradict results 
within the current body of literature. Three studies have previously produced results indicating 
TMS is able to produce improvements in neurocognitive performance (Bentwich, et al., 2011; 
Lee, et al., 2016; Rabey & Dobrenevsky, 2016). However, it is important to note that each of 
these studies incorporated a form of cognitive training during the TMS administration 
procedures. These results in conjunction with the results of the current study appear to indicate 
that TMS alone may not be efficacious in improving neurocognitive functioning independent of 
depressive symptoms. Neurocognitive function is often seen as a dimension of depressive 
disorders – in these instances, TMS is able to treat neurocognitive function; however, TMS in 
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combination with cognitive training (deemed TMS-Cog; Bentwich, et al., 2011; Lee, et al., 2016; 
Rabey & Dobrenevsky, 2016) may produce neurocognitive improvements above changes 
attributed to depressive symptom improvement.  
Limitations and Future Considerations 
 This study, like all studies, is not without its limitations. The largest limitation in this 
study concerns the sample. Because this study used archival data, i.e. data that had been 
previously collected, the active researchers here had very little control over sample selection and 
methodologies implemented. As a result, some potential limitations arose.  
 Much of the previous research in MCI/dementia focuses on elderly/geriatric populations. 
Analysis of the demographics statistics, particularly average age of each group (MCI = 47.76; 
non-MCI = 42.17), likely do not allow the present results to be generalized to elderly/geriatric 
populations. As a result, these results may not generalize to elderly individuals diagnosed with 
MCI/dementia not attributable to depressive symptomology. Also, stemming from sample 
selection, present researchers cannot be sure if participants within the sample may be diagnosed 
with true MCI or if any neurocognitive impairments are the results of a depressive 
pseudodementia presentation. If the observed neurocognitive impairments within the MCI group 
were due to a depressive pseudodementia presentation, then the neurocognitive results of this 
research study may be better explained. However, because the etymology of neurocognitive 
impairments in the present sample cannot be determined, this provides a significant limitation of 
this study. 
 Another potential limitation relates to this study’s inability to differentiate between 
amnestic MCI and non-amnestic MCI. Much of the MCI research body emphasizes the 
differentiation between these two sub-categories of MCI because they each may have different 
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diagnostic implications and potential disease progressions. However, after further classifying the 
MCI group into amnestic and non-amnestic MCI, the sizes of each group did not meet power 
criteria and were significantly different from each other (amnestic MCI n = 24; non-amnestic 
MCI n = 14). As a result, any comparative analyses performed between these two groups would 
likely not produce reliable results, and therefore were omitted from this study’s design.  
 It should also be noted that this study lacked a sham-TMS or other form of no-treatment 
control group. While the non-MCI group provided a comparison group for the MCI group in the 
depressive symptom analyses, this study lacked a no-treatment or treatment-as-usual control 
group. As a result, this study could not control for potential placebo effects, nor could it provide 
any statements as to treatment efficacy above other forms of treatment. However, one could 
extrapolate the presence of a true treatment effect among both the MCI and non-MCI group for 
TMS treatment, as the effect sizes observed within this study are comparable, if not stronger, 
than those found in previous studies (Sabesan, et al., 2015). Regardless, the lack of a no-
treatment control group within this study should be considered when interpreting these results. 
 The archival data used for this study also did not include follow-up examination data. As 
a result, this study lacked follow-up assessment results and therefore cannot make statements 
regarding the continuation of treatment effects post-treatment. Previous research has shown TMS 
to produce long-lasting treatment effects even after cessation of treatment (Machado, et al., 2013; 
Simpson, et al., 2009). In fact, some research indicates that TMS may have long-lasting benefits 
for up to 84.2% of patients, with effects maintained at 6-month follow-up (treatment benefits 
defined by the absence of depressive symptom relapse; Janicak, et al., 2010). Therefore, it could 
be argued that those long-lasting effects likely generalize to this research study; however, the 
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lack of follow-up measures remains a limiting factor in speaking to the long-term efficacy of 
TMS treatment for individuals with MCI.  
 Additionally, the extracted data set used for this study did not contain complete 
information on participant’s racial or ethnic background. Of the 68 total participants data points 
included in this study, 28 did not report any racial or ethnic background. Of the remaining 48 
participants, 47 of whom identified as Caucasian, and one identified as African American. 
Because of this distribution, this study could not examine potential racial differences in TMS 
treatment outcomes. 
 Another potential limitation is the assessment battery used to assess neurocognitive 
functioning (CNS-VS). While the CNS-VS has shown promising reliability and validity, 
particularly in its uses for identification of MCI, diagnostic specificity, and its uses for research 
within a clinical setting (Gualtieri, 2004; Gualtieri & Johnson, 2005; Gualtieri & Johnson, 2006; 
Gualtieri & Johnson, 2008; Gualtieri, Johnson, & Benedict, 2006), it is possible that a more 
extensive neurocognitive assessment battery that targets each specific neurocognitive domain 
(i.e. executive functioning, processing speed, etc.) may provide a more accurate representation of 
each participant’s neurocognitive profile at baseline assessment and also as they progress in 
TMS treatment. 
 Also related to assessment, the BDI-II has a number of questions that assess the cognitive 
symptoms of depression (i.e. “Concentration Difficulty” and “Indecisiveness”). Researchers 
examining the psychometric properties of the BDI-II have performed factor analyses and 
identified these cognitive questions to be an independent factor, labeled the “cognitive-affective” 
factor (Brown, Kaplan, & Jason, 2012; Dozois, Dobson, & Ahnberg, 1998, p. 84). This must be 
taken into consideration when analyzing the non-significance of the neurocognitive improvement 
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after controlling for depressive symptom change. Because the variance of depressive symptom 
severity (as assessed by the BDI-II) was removed from the model, the resulting neurocognitive 
scores (as assessed by the CNS-VS) also had neurocognitive variance assessed by the BDI-II 
removed from the model. That being said, it is possible that the results from these particular 
analyses underestimate the effects of neurocognitive improvement as a result of TMS treatment 
over time independent of depressive symptom improvement. While the cognitive-affective factor 
of the BDI-II could have been removed separately from the BDI-II total scores before covarying 
depressive symptoms from the neurocognition indices, doing so would likely decrease the 
overall reliability and validity of the BDI-II total scores, thus introducing further error into the 
overall model (Brown, et al., 2012; Dozois, et al., 1998; Storch, Roberti, & Roth, 2004). 
 A final limitation within this study regards the positioning of the TMS coil during TMS 
treatment. The EVMS TMS Treatment Program uses the Pascual-Leone method of coil 
placement in which the TMS coil is placed 5cm rostrally from the MT area of the primary motor 
cortex to identify the DLPFC, and 2cm rostrally to identify the SMA. While the Pascual-Leone 
method of coil placement is commonly used, both in the clinical and research settings, some 
neuronavigation studies have shown that fMRI-guided TMS coil placement may yield the 
strongest behavioral effects in comparison to EEG-guided approach and the Pascual-Leone 
method of coil placement (Sack, et al., 2009). Based on this information, using the Pascual-
Leone method of coil placement may have been a potential contributing factor into the lack of 
treatment improvements in neurocognitive performance independent of depressive symptom 
improvement.  
 The previously mentioned limitations warrant careful analysis of the findings and 
interpretations of this study, specifically the neurocognitive performance results. Many of these 
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limiting factors could provide potential explanations as to why neurocognitive improvements 
were not found to remain significant after controlling for depressive symptom improvements. 
Also, while the depressive symptom improvement results are tantalizing, long-term maintenance 
of treatment gains for individuals with MCI is not known. As a result, future research into this 
area should attempt to rectify some of these limitations in order to improve the generalizability 
and overall impact of results. The optimal research method that could address many of these 
limitations would be a randomized clinical trial (RCT) which includes a sham-TMS control 
condition.  
Conclusions 
 The present study is among the first empirical studies to actively examine the treatment 
efficacy for TMS in treating depression among individuals with impaired cognitive functioning. 
Additionally, this study is among the first to provide empirical support for the comparative 
efficacy of TMS by comparing treatment outcomes among individuals with MCI to treatment 
outcomes among individuals with average neurocognitive functioning. Overall, this study 
provides support for the statement that TMS may be an efficacious treatment method for treating 
treatment-resistant, or refractory, depression among individuals diagnosed with MCI. The results 
of this study also demonstrate that TMS alone may not be sufficient in treating cognitive 
impairments among individuals with MCI, and treatment protocols with this desired outcome 
should incorporate some form of cognitive training, as suggested by the literature.  
 This study also provides further support to the interconnectedness of depressive disorders 
and cognitive impairment and the presence of depressive pseudodementia. The results showed 
significant improvements among multiple neurocognitive domains, but these improvements 
appeared to occur as a function of improving depressive symptoms, indicating that these 
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cognitive impairments were likely caused by the depressive symptoms. In turn, it becomes 
increasingly clear that depression and MCI can be significantly connected, and therefore accurate 
differential diagnosis between these two disorders is paramount. 
 Further research is still needed in generating an empirical body of support for the efficacy 
of TMS in treating depression among individuals diagnosed with MCI. While this study 
produced promising results, hopefully it will encourage future researchers to examine this topic 
even further to determine whether or not TMS may provide an efficacious and effective method 
of treating depression for this population.  
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APPENDIX A 
 EVMS TMS REGISTRY CONSENT FORM 
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APPENDIX B 
POWER ANALYSIS 
 
 Cohen’s d = .35 (Sabesan, et al., 2015) was converted to ηp2 = .030 with the following 
formula, as found in Cohen (1988, p. 281-285): f = d/2; ηp2 = f2/(1+f2). 
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